# Leif W. Ellisen

Source: https://onco.cc/people/leif-ellisen/  
OnCo record `leif-ellisen` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Runs breast medical oncology at MGH and studies the tumour-suppressor biology behind hereditary and triple-negative breast cancer.

## Summary

Leif W. Ellisen is Program Director of Breast Medical Oncology at Massachusetts General Hospital Cancer Center. He is a physician-scientist known for studying the tumour-suppressor biology behind hereditary and triple-negative breast cancer, with laboratory work on the p53 family members p63 and p73 and the DNA damage response in breast and squamous cancers. His selected paper shows that the p63 isoform delta-Np63-alpha represses anti-proliferative genes through H2A.Z deposition. He runs MGH's breast oncology programme while continuing research on TP53, BRCA1 and BRCA2 and cancer predisposition.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Program Director, Breast Medical Oncology
- Specialisms: Breast cancer genetics; p53 family and p63; Cancer predisposition

## Sources

- MGH profile: https://www.massgeneral.org/doctors/17039/leif-ellisen
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Ellisen%20LW%5BAuthor%5D

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [TP53](https://onco.cc/targets/tp53/)
- institutions: [Massachusetts General Hospital Cancer Center](https://onco.cc/institutions/mgh/)
- journals: [Genes & Development](https://onco.cc/journals/genes-and-development/)

---
JSON: https://onco.cc/api/v1/entities/leif-ellisen.json